|
Delayed
Nasdaq
21:00:00 15/06/2026 BST
|
5-day change | 1st Jan Change | ||
| 23.50 USD | +0.09% |
|
-.--% | +159.10% |
| 06-16 | Assertio Holdings Completes Merger With Zydus Lifesciences | MT |
| 06-16 | Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026 | CI |
| Market Cap | 152M 131M 124M 112M 211M 14.51B 212M 1.47B 566M 7.38B 570M 558M 23.32B | P/E 2024 |
-3.79x | P/E 2025 | -1.91x |
|---|---|---|---|---|---|
| Enterprise Value | 129M 111M 105M 95.18M 179M 12.3B 179M 1.25B 480M 6.26B 483M 473M 19.77B | EV / Sales 2024 |
0.19x | EV / Sales 2025 | 0.3x |
| Free-Float |
99.05% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript : Assertio Holdings
| 1 day | +0.09% | ||
| 3 months | +0.13% | ||
| 6 months | +104.35% | ||
| Current year | +159.10% |
| Current year | 9.11 | 23.5 | |
| 1 year | 8.61 | 23.5 | |
| 3 years | 7.71 | 45.75 | |
| 5 years | 7.71 | 120.15 | |
| 10 years | 7.71 | 1,621.19 |
| Director | Title | Age | Since |
|---|---|---|---|
Ravi Yadavar
BRD | Director/Board Member | 26 | 15/06/2026 |
Punit Patel
BRD | Director/Board Member | - | 15/06/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/05/26 | Don | Chairman | -13,332 | 0.2069% | ||
| 05/05/26 | Free | Chairman | 4,851 | 0.0753% | ||
| 05/05/26 | Free | Director | 4,851 | 0.0753% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.09% | -.--% | +94.57% | -48.63% | 152M | ||
| -0.65% | -2.93% | +47.52% | +87.34% | 1,001B | ||
| -0.29% | -3.51% | +48.78% | +63.27% | 642B | ||
| +0.83% | +0.26% | +16.76% | +72.52% | 451B | ||
| -0.38% | -3.59% | +28.24% | +35.57% | 340B | ||
| -0.09% | -13.54% | +10.08% | +26.87% | 263B | ||
| -0.43% | -2.48% | -2.07% | +11.48% | 247B | ||
| -1.34% | -13.70% | +33.47% | +44.18% | 207B | ||
| -3.44% | -7.51% | -20.08% | -59.58% | 197B | ||
| -0.75% | -4.82% | +21.94% | +86.55% | 180B | ||
| Average | -0.65% | -4.96% | +27.92% | +31.96% | 352.65B | |
| Weighted average by Cap. | -0.52% | -4.33% | +29.80% | +55.48% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 125M 108M 102M 92.4M 173M 11.94B 174M 1.21B 466M 6.07B 469M 459M 19.19B | 119M 102M 96.85M 87.78M 165M 11.34B 166M 1.15B 442M 5.77B 446M 436M 18.23B |
| Net income | -21.58M -18.59M -17.61M -15.96M -29.94M -2.06B -30.09M -209M -80.41M -1.05B -81.05M -79.27M -3.31B | -30.38M -26.17M -24.78M -22.46M -42.14M -2.9B -42.35M -294M -113M -1.48B -114M -112M -4.67B |
| Net Debt | -59.79M -51.51M -48.78M -44.21M -82.94M -5.71B -83.36M -579M -223M -2.91B -225M -220M -9.18B | -23.15M -19.95M -18.89M -17.12M -32.12M -2.21B -32.28M -224M -86.26M -1.13B -86.95M -85.04M -3.56B |
Employees
53
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ASRT Stock
Select your edition
All financial news and data tailored to specific country editions
















